Machine Learning

i2i Population Health Partners with OptMyCare

i2i Population Health, an industry leader in providing comprehensive population health solutions, has a highly sophisticated workflow platform that is user friendly and very effective in capturing inefficiencies in the healthcare system. “By accurately identifying members at high emerging risk through OptMyCare’s analytics, i2i can now provide its clients with predictive solutions to further mitigate disease progression and decrease cost,” says Justin Neece, CEO and President of i2i. OptMyCare, a healthcare predictive and descriptive analytics SaaS platform, has partnered with i2i which provides comprehensive population health services to over 30 million Americans across 340 clients in Federally Qualified Health Centers (FQHC), Primary Care Associations, Clinically Integrated Networks, Hospitals, and Health Plans in 39 states. “This partnership will provide OptMyCare with an opportunity to incorporate its machine learning, risk stratification, and patient-specific prescriptive solution into i2i’s workflow,” according to Dr. Saravanan Bala, CEO of OptMyCare.

This partnership will augment efficiencies for hospitals and FQHC providers with comprehensive risk stratification across all known disease conditions, providing evidence-based recommendations at a patient level for care management teams. With increasing shortages in the healthcare workforce, the i2i Population Health and OptMyCare partnership would allow care managers and nurses to spend more time with patients at higher risk for emerging disease and its complications. This approach could save the healthcare system several million dollars while also improving patient wellness.

Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!

Related posts

ML Platform Hello Alice Raises $21 Million

PR Newswire

US Patent Issued for Exactech’s Predict+™

Business Wire

My Intelligent Machines Launches New Software for Drug Development

Business Wire